Health Care & Life Sciences » Biotechnology | Cohbar Inc.

Cohbar Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
2.40
30.70
58.00
57.50
79.10
Gross Income
2.40
30.70
58.00
57.50
79.10
SG&A Expense
1,810.20
3,843.60
6,018.60
9,801.70
15,255.20
EBIT
1,812.60
3,874.30
6,076.60
9,859.30
15,334.30
Non Operating Income/Expense
0.50
1.50
-
-
-
Interest Expense
7.20
7.20
7.80
3.60
557.10
Pretax Income
1,819.70
3,878.20
6,075.00
9,833.20
15,705.90
Consolidated Net Income
1,819.70
3,878.20
6,075.00
9,833.20
15,705.90
Net Income
1,819.70
3,878.20
6,075.00
9,833.20
15,705.90
Net Income After Extraordinaries
1,819.70
3,878.20
6,075.00
9,833.20
15,705.90
Net Income Available to Common
1,819.70
3,878.20
6,075.00
9,833.20
15,705.90
EPS (Basic)
0.14
0.12
0.18
0.26
0.38
Basic Shares Outstanding
12,915.30
32,044.30
33,130.40
37,478.90
41,254.40
EPS (Diluted)
0.14
0.12
0.18
0.26
0.38
Diluted Shares Outstanding
12,915.30
32,044.30
33,130.40
37,478.90
41,254.40
EBITDA
1,810.20
3,843.60
6,018.60
9,801.70
15,255.20
Non-Operating Interest Income
0.60
4.80
9.40
29.70
185.60

About Cohbar

View Profile
Address
1455 Adams Drive
Pasadena California 94025
United States
Employees -
Website http://www.cohbar.com
Updated 07/08/2019
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Pasadena, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.